# Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk

> **NCT02945033** · PHASE3 · RECRUITING · sponsor: **University Hospital, Rouen** · enrollment: 264 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** aspirin intake
- **DRUG:** placebo intake
- **PROCEDURE:** Surgical resection of colonic adenocarcinoma stage III or II high risk
- **BIOLOGICAL:** Molecular analysis of exon 9 and 20 of PI3K
- **BIOLOGICAL:** blood intake

## Key facts

- **NCT ID:** NCT02945033
- **Lead sponsor:** University Hospital, Rouen
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-07-12
- **Primary completion:** 2028-07
- **Final completion:** 2028-07
- **Target enrollment:** 264 (ESTIMATED)
- **Last updated:** 2026-02-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02945033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02945033, "Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02945033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*